Skip to main content
SpringerLink
Log in

Alglucerase: which patients warrant this expensive treatment?

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. British National Formulary. No. 35. London: The Pharmaceutical Press, 1998 Mar: 423–4

  2. Hollak CEM, Aerts JMFG, van Oers MHJ. Alglucerase. Practical guidance on appropriate dosage and administration in patients with Gaucher disease. BioDrugs 1998 Jan; 9(1): 11–23

    Article  PubMed  CAS  Google Scholar 

  3. Alglucerase is effective but high cost limits use. Drug Ther Perspect 1993 Jun 7; 1(10): 15–6

    Google Scholar 

  4. Verderese CL, Graham OC, Holder-McShane CA, et al. Gaucher’s disease: a pilot study of the symptomatic responses to enzyme replacement therapy. J Neurosci Nurs 1993; 25: 296–301

    Article  PubMed  CAS  Google Scholar 

  5. NIH Technology Assessment Panel on Gaucher Disease. Gaucher disease: current issues in diagnosis and treatment. JAMA 1996; 275: 548–53

    Article  Google Scholar 

  6. Beutler E, Demina A, Laubscher K, et al. The clinical course of treated and untreated Gaucher disease: a study of 45 patients. Blood Cells Mol Dis 1995; 21: 86–108

    Article  PubMed  CAS  Google Scholar 

  7. Zimran A, Kay AC, Gelbart T, et al. The natural history of adult type Gaucher disease: clinical laboratory, radiologic and genetic features of 53 patients. Medicine 1992; 71: 337–53

    Article  PubMed  CAS  Google Scholar 

  8. Richards S, Olson T, McPherson J. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 1993; 82(5): 1402–9

    PubMed  CAS  Google Scholar 

  9. Sidransky E, Dietrich K, Ginns E. False-positive pregnancy tests in Gaucher’s disease [letter]. Lancet 1994; 344: 1156

    Article  PubMed  CAS  Google Scholar 

  10. Cohen Y, Elstein D, Abrahamov A, et al. HCG contamination of alglucerase: clinical implications in low-dose regimen. Am J Hematol 1994; 47: 235–6

    Article  PubMed  CAS  Google Scholar 

  11. Granovski-Grisaru S, Aboulafia Y, Diamant YZ, et al. Gynaecologic and obstetric aspects of Gaucher’s disease: a survey of 53 patients. Am J Obstet Gynecol 1995; 172: 1184–90

    Article  Google Scholar 

  12. Elstein D, Granovski-Grisaru S, Rabinovitz R, et al. Use of enzyme replacement therapy for Gaucher disease during pregnancy. Am J Obstet Gynecol 1997 Dec; 177: 1509–12

    Article  PubMed  CAS  Google Scholar 

  13. Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995; 122: 33–9

    PubMed  CAS  Google Scholar 

  14. Zimran A, Elstein D, Levy-Lahad E. Replacement therapy with imiglucerase for type 1 Gaucher’s disease. Lancet 1995; 345: 1479–80

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alglucerase: which patients warrant this expensive treatment?. Drugs Ther. Perspect 12, 5–8 (1998). https://doi.org/10.2165/00042310-199812100-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199812100-00002

Keywords

Search

Navigation